Program
RBD4059
A development code.
Its studies are mostly in Coronary Artery Disease, led by Suzhou Ribo Life Science.
Furthest: phase 2, since Nov 4, 20243 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Ribo Life Science | 31 open or running | phase 2since Nov 4, 2024 | Nov 21, 2022 | Aug 2027phase 1 · NCT07930767 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 21, 2022First study: phase 1 study in Healthy VolunteersFirst studyNCT05653037 · 32 enrolled · Australia
- Nov 4, 2024Phase 2 study in Stable Coronary Artery Disease CADNCT06717074 · 30 enrolled · Sweden
- Nov 5, 2026Phase 1 study in HealthyNCT07930767 · 30 planned
Ahead
- Aug 2027Primary completion: phase 1 study in HealthyNCT07930767
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07930767Healthy | 1 | Not yet recruiting | Aug 2027 | 30 |
| NCT06717074Stable Coronary Artery Disease CAD · Sweden | 2 | Completed | Apr 29, 2026 | 30 |
| NCT05653037Healthy Volunteers · Australia | 1 | Completed | Oct 1, 2024 | 32 |
How it is read
Names in the registry
- “RBD4059”, 3 entries
Codes read as this program: RBD4059.
Conditions, from the studies’ own filings
- Coronary Artery Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.